Endothelial arginase II and atherosclerosis

Sungwoo Ryoo, Dan E Berkowitz, Hyun Kyo Lim

Research output: Contribution to journalArticle

Abstract

Atherosclerotic vascular disease is the leading cause of morbidity and mortality in developed countries. While it is a complex condition resulting from numerous genetic and environmental factors, it is well recognized that oxidized low-density lipoprotein produces pro-atherogenic effects in endothelial cells (ECs) by inducing the expression of adhesion molecules, stimulating EC apoptosis, inducing superoxide anion formation and impairing protective endothelial nitric oxide (NO) formation. Emerging evidence suggests that the enzyme arginase reciprocally regulates NO synthase and NO production by competing for the common substrate L-arginine. As oxidized LDL (OxLDL) results in arginase activation/upregulation, it appears to be an important contributor to endothelial dysfunction by a mechanism that involves substrate limitation for endothelial NO synthase (eNOS) and NO synthesis. Additionally, arginase enhances production of reactive oxygen species by eNOS. Arginase inhibition in hypercholesterolemic (ApoE-/-) mice or arginase II deletion (ArgII-/-) mice restores endothelial vasorelaxant function, reduces vascular stiffness and markedly reduces atherosclerotic plaque burden. Furthermore, arginase activation contributes to vascular changes including polyamine-dependent vascular smooth muscle cell proliferation and collagen synthesis. Collectively, arginase may play a key role in the prevention and treatment of atherosclerotic vascular disease.

Original languageEnglish (US)
Pages (from-to)3-11
Number of pages9
JournalKorean Journal of Anesthesiology
Volume61
Issue number1
DOIs
StatePublished - Jul 2011

Fingerprint

Arginase
Atherosclerosis
Nitric Oxide
Vascular Diseases
Nitric Oxide Synthase
Endothelial Cells
Vascular Stiffness
Nitric Oxide Synthase Type III
Polyamines
Apolipoproteins E
Atherosclerotic Plaques
Vasodilator Agents
Vascular Smooth Muscle
Developed Countries
Superoxides
Smooth Muscle Myocytes
Blood Vessels
Arginine
Reactive Oxygen Species
Up-Regulation

Keywords

  • Arginase
  • Atherosclerosis
  • Endothelial dysfunction
  • Endothelial nitric oxide synthase
  • Vascular smooth muscle cell

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Endothelial arginase II and atherosclerosis. / Ryoo, Sungwoo; Berkowitz, Dan E; Lim, Hyun Kyo.

In: Korean Journal of Anesthesiology, Vol. 61, No. 1, 07.2011, p. 3-11.

Research output: Contribution to journalArticle

Ryoo, Sungwoo ; Berkowitz, Dan E ; Lim, Hyun Kyo. / Endothelial arginase II and atherosclerosis. In: Korean Journal of Anesthesiology. 2011 ; Vol. 61, No. 1. pp. 3-11.
@article{4a48204daab846f19f8cd0894603c0cc,
title = "Endothelial arginase II and atherosclerosis",
abstract = "Atherosclerotic vascular disease is the leading cause of morbidity and mortality in developed countries. While it is a complex condition resulting from numerous genetic and environmental factors, it is well recognized that oxidized low-density lipoprotein produces pro-atherogenic effects in endothelial cells (ECs) by inducing the expression of adhesion molecules, stimulating EC apoptosis, inducing superoxide anion formation and impairing protective endothelial nitric oxide (NO) formation. Emerging evidence suggests that the enzyme arginase reciprocally regulates NO synthase and NO production by competing for the common substrate L-arginine. As oxidized LDL (OxLDL) results in arginase activation/upregulation, it appears to be an important contributor to endothelial dysfunction by a mechanism that involves substrate limitation for endothelial NO synthase (eNOS) and NO synthesis. Additionally, arginase enhances production of reactive oxygen species by eNOS. Arginase inhibition in hypercholesterolemic (ApoE-/-) mice or arginase II deletion (ArgII-/-) mice restores endothelial vasorelaxant function, reduces vascular stiffness and markedly reduces atherosclerotic plaque burden. Furthermore, arginase activation contributes to vascular changes including polyamine-dependent vascular smooth muscle cell proliferation and collagen synthesis. Collectively, arginase may play a key role in the prevention and treatment of atherosclerotic vascular disease.",
keywords = "Arginase, Atherosclerosis, Endothelial dysfunction, Endothelial nitric oxide synthase, Vascular smooth muscle cell",
author = "Sungwoo Ryoo and Berkowitz, {Dan E} and Lim, {Hyun Kyo}",
year = "2011",
month = "7",
doi = "10.4097/kjae.2011.61.1.3",
language = "English (US)",
volume = "61",
pages = "3--11",
journal = "Korean Journal of Anesthesiology",
issn = "2005-6419",
publisher = "Korean Society of Anesthesiologists",
number = "1",

}

TY - JOUR

T1 - Endothelial arginase II and atherosclerosis

AU - Ryoo, Sungwoo

AU - Berkowitz, Dan E

AU - Lim, Hyun Kyo

PY - 2011/7

Y1 - 2011/7

N2 - Atherosclerotic vascular disease is the leading cause of morbidity and mortality in developed countries. While it is a complex condition resulting from numerous genetic and environmental factors, it is well recognized that oxidized low-density lipoprotein produces pro-atherogenic effects in endothelial cells (ECs) by inducing the expression of adhesion molecules, stimulating EC apoptosis, inducing superoxide anion formation and impairing protective endothelial nitric oxide (NO) formation. Emerging evidence suggests that the enzyme arginase reciprocally regulates NO synthase and NO production by competing for the common substrate L-arginine. As oxidized LDL (OxLDL) results in arginase activation/upregulation, it appears to be an important contributor to endothelial dysfunction by a mechanism that involves substrate limitation for endothelial NO synthase (eNOS) and NO synthesis. Additionally, arginase enhances production of reactive oxygen species by eNOS. Arginase inhibition in hypercholesterolemic (ApoE-/-) mice or arginase II deletion (ArgII-/-) mice restores endothelial vasorelaxant function, reduces vascular stiffness and markedly reduces atherosclerotic plaque burden. Furthermore, arginase activation contributes to vascular changes including polyamine-dependent vascular smooth muscle cell proliferation and collagen synthesis. Collectively, arginase may play a key role in the prevention and treatment of atherosclerotic vascular disease.

AB - Atherosclerotic vascular disease is the leading cause of morbidity and mortality in developed countries. While it is a complex condition resulting from numerous genetic and environmental factors, it is well recognized that oxidized low-density lipoprotein produces pro-atherogenic effects in endothelial cells (ECs) by inducing the expression of adhesion molecules, stimulating EC apoptosis, inducing superoxide anion formation and impairing protective endothelial nitric oxide (NO) formation. Emerging evidence suggests that the enzyme arginase reciprocally regulates NO synthase and NO production by competing for the common substrate L-arginine. As oxidized LDL (OxLDL) results in arginase activation/upregulation, it appears to be an important contributor to endothelial dysfunction by a mechanism that involves substrate limitation for endothelial NO synthase (eNOS) and NO synthesis. Additionally, arginase enhances production of reactive oxygen species by eNOS. Arginase inhibition in hypercholesterolemic (ApoE-/-) mice or arginase II deletion (ArgII-/-) mice restores endothelial vasorelaxant function, reduces vascular stiffness and markedly reduces atherosclerotic plaque burden. Furthermore, arginase activation contributes to vascular changes including polyamine-dependent vascular smooth muscle cell proliferation and collagen synthesis. Collectively, arginase may play a key role in the prevention and treatment of atherosclerotic vascular disease.

KW - Arginase

KW - Atherosclerosis

KW - Endothelial dysfunction

KW - Endothelial nitric oxide synthase

KW - Vascular smooth muscle cell

UR - http://www.scopus.com/inward/record.url?scp=80051813635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051813635&partnerID=8YFLogxK

U2 - 10.4097/kjae.2011.61.1.3

DO - 10.4097/kjae.2011.61.1.3

M3 - Article

VL - 61

SP - 3

EP - 11

JO - Korean Journal of Anesthesiology

JF - Korean Journal of Anesthesiology

SN - 2005-6419

IS - 1

ER -